Synta Pharmaceuticals (SNTA +11.6%) pops after reporting encouraging results from its Phase 2b...

|By:, SA News Editor

Synta Pharmaceuticals (SNTA +11.6%) pops after reporting encouraging results from its Phase 2b Galaxy trial of ganetespib - the company's lead Hsp90 inhibitor - as second-line treatment for advanced non-small cell lung cancer. The company says test results showed good tolerability for the combination of ganetespib and docetaxel as well as meaningful improvements in overall survival in adenocarcinoma patients receiving the drug combination.